北京招聘

Assistant for QA & PV (1-year contract)

Responsibilities:

· Assist in documentation of product complaints and adverse events received from local customers

· Assist in recall coordination as needed

· Assist in the quality activities of the distributors; including maintaining quality agreement/PV agreement as needed

Education and Qualifications:

· Degree in Pharmacy or B.S. in science or technical field (such as chemistry, microbiology, engineering, biology, etc.)

· Fresh graduated or less working experience or intern will be also considered.

· Detail-oriented, proactive with good communication skills

· Good habit on documents archive.

· Good command on English speaking and writing

· Immediate available is Preferred

Organizational Relationships:

The position reports to the Manager, Regulatory Affairs, China.

Working Conditions:

Normal office environment, but requires regional travel to meet with customers, vendors, plants, subsidiaries, and government agencies.

Disclaimer:

The above statements are intended to describe the general nature and level of work being performed by employees assigned to this classification. They are not intended to be construed as an exhaustive list of all responsibilities, duties and skills required of employees assigned to this position.

Mallinckrodt, the Pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions. We are the largest U.S. supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. We are also the largest global supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals, contrast media, and delivery systems. Mallinckrodt encompasses more than 5,500 dedicated employees around the globe, all focused on our core values of quality, integrity and service to meet the needs of patients globally. Please visit www.mallinckrodt.com to learn more about our business.

Established as G. Mallinckrodt & Company in 1867, the $2 billion St. Louis-based business was acquired by Tyco International in 2000. In 2007, Tyco spun off its healthcare business into Covidien, a leading global healthcare products company. On December 15, 2011, Covidien announced plans to spin off Mallinckrodt as a standalone public company. On February 1, 2013, Mallinckrodt submitted the initial filing of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission. Covidien expects to complete the spin-off by mid-2013.

Mallinckrodt's mission is to reveal and relieve disease for a healthier world, and our vision expands on our mission - a world made healthier by building on our heritage of distinctive capabilities to provide patients with pharmaceuticals that reveal and relieve disease.